← All Nuvation Bio INC filings

Nuvation Bio INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
NUVB
Nuvation Bio INC
10-K: Nuvation Bio's IBTROZI Drives Revenue Amidst Rising Costs
Nuvation Bio reports its first product revenue from IBTROZI's U.S. launch, but faces increased operating losses and substantial funding needs for its pipeline development.
NYSE
NUVB
Nuvation Bio INC
10-K: Nuvation Bio Inc. Announces 2024 Financial Results and Provides Business Update
Nuvation Bio Inc. reports its 2024 financial results, highlighting progress in its oncology pipeline, including the FDA's acceptance of the NDA for taletrectinib.
NYSE
NUVB
Nuvation Bio INC
10-K/A: Nuvation Bio Files Amended 10-K Report Including Key Governance and Compensation Details
Nuvation Bio Inc. files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.
NYSE
NUVB
Nuvation Bio INC
10-K: Nuvation Bio Inc. Files 10-K Report, Highlights Clinical Pipeline Progress and Financial Position
Nuvation Bio Inc. released its 10-K filing, detailing its clinical-stage oncology pipeline, financial status, and strategic direction for 2023.